Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Ferroportin and iron regulation in breast cancer progression and prognosis.
- Zandra K. Pinnix, L. Miller, +9 authors F. Torti
- Biology, MedicineScience translational medicine
- 4 August 2010
It is shown that decreased ferroportin gene expression is associated with a significant reduction in metastasis-free and disease-specific survival that is independent of other breast cancer risk factors and identifies an extremely favorable cohort of breast cancer patients who have a 10-year survival of >90%.
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
Patients randomly assigned to the high-dose regimen of adjuvant chemotherapy had significantly longer disease-free and overall survival if their tumors had c-erbB-2 overexpression, a useful marker to identify a subgroup of patients more likely than others to benefit from high doses of chemotherapy.
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
- A. Thor, D. Berry, +9 authors E. Liu
- MedicineJournal of the National Cancer Institute
- 16 September 1998
The hypothesis that patients whose breast tumors exhibit high erbB-2 expression benefit from dose-intensive CAF should be further validated before clinical implementation.
Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediates Resistance to Mitoxantrone via Glutathione-Dependent Drug Efflux
- C. Morrow, Christina Peklak-Scott, B. Bishwokarma, T. Kute, P. K. Smitherman, A. Townsend
- Biology, MedicineMolecular Pharmacology
- 1 April 2006
The results suggest that MRP1—like the alternative MX transporters ABCG2 and ABCB1 (MDR1, P-glycoprotein)—can significantly influence tumor cell sensitivity to and pharmacological disposition of MX.
Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells.
Investigation of the influence of the peroxisome proliferator-activated receptor gamma (PPARgamma) agonists on the proliferation, apoptosis and tumorigenesis of breast cancer cells shows that induction of apoptosis may be the primary biological response resulting from PPARGamma activation in some breast cancer Cells and suggests a potential role for PPAR Gamma ligands for the treatment of breast cancers.
5-Oxo-ETE analogs and the proliferation of cancer cells.
Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast
- D. Hedley, G. Clark, C. Cornelisse, D. Killander, T. Kute, D. Merkel
- Biology, MedicineBreast Cancer Research and Treatment
- 1 October 1993
SummaryThis is the consensus statement regarding the clinical utility of DNA cytometry in breast cancer from the DNA Cytometry Consensus Conference held in Prout's Neck, Maine, USA, on October 1–4,…
Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification.
Characterisation of two human cell lines established from biopsy specimens of breast carcinomas revealed that both are highly aneuploid containing multiple clonal chromosome alterations, have doubling times near 100 h, and are oestrogen and progesterone receptor negative.
Molecular heterogeneity of cytosolic forms of estrogen receptors from human breast tumors.
The findings with diethylaminoethyl cellulose chromatography suggest that the molecular composition of the 8S species of estrogen receptors from hormonally responsive tumors is different from that of certain uresponsive neoplasms.
The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer
Flow cytometry data may provide independent information related to survival in N–women, but additional research in a larger number of patients is needed to define its precise role in patient management.